Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$49.09 USD

49.09
3,285,409

-0.04 (-0.08%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $49.00 -0.09 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (202 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus

by Zacks Equity Research

Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More

by Kinjel Shah

AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by 1%.

Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study

by Zacks Equity Research

Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.

Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?

by Zacks Equity Research

Regeneron (REGN) shares gain 10% year to date on Eylea HD's approval and Dupixent's momentum. Pipeline progress is impressive as well.

TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug

by Zacks Equity Research

Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop olanzapine LAI for treating schizophrenia.

AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View

by Zacks Equity Research

AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.

TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised

by Zacks Equity Research

TEVA reports decent third-quarter results. The company raises its revenue guidance for 2023 for the second time this year while keeping the EPS range intact.

Regeneron (REGN) Q3 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in third-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, fall yet again.

BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut

by Zacks Equity Research

BioMarin's (BMRN) Q3 earnings are in line with estimates but miss the mark on sales. The company lowered its 2023 guidance due to global pricing and reimbursement delays for Roctavian.

Sanofi (SNY) Beats on Q3 Earnings, to Spin-Off Consumer Unit

by Zacks Equity Research

Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It announces plans to separate its Consumer unit into a new public listed company.

Kinjel Shah headshot

Pharma Stock Roundup: SNY, MRK, NVS Report Q3 Earnings, FDA Okays PFE, LLY Products

by Kinjel Shah

Merck (MRK), Sanofi (SNY) and Novartis (NVS) report third-quarter results. FDA approves Pfizer's (PFE) Penbraya and Eli Lilly's (LLY) Omvoh

Regeneron (REGN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on the performance of lead drug Eylea and the uptake of Eylea HD when Regeneron (REGN) reports its third-quarter 2023 results.

Lilly (LLY) Moves 4.5% Higher: Will This Strength Last?

by Zacks Equity Research

Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Mirati (MRTX) Gets Buyout Offer From Bristol Myers for $4.8B

by Zacks Equity Research

Sanofi (SNY) is set to acquire Mirati (MRTX) for $58 per share in cash along with a contingent value right of $12 per share, tied to a regulatory milestone.

Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout

by Zacks Equity Research

A Bloomberg article suggests that pharma giant Sanofi (SNY) is exploring a potential acquisition deal for small cancer drugmaker Mirati Therapeutics (MRTX).

Kinjel Shah headshot

Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates

by Kinjel Shah

Eli Lilly (LLY) offers to buy POINT Biopharma for approximately $1.4 billion. Sanofi (SNY) partners with Teva for co-developing immunology candidate.

The Zacks Analyst Blog Highlights Alphabet, Sanofi, Mondelez International, Uber Technologies and Airbnb

by Zacks Equity Research

Alphabet, Sanofi, Mondelez International, Uber Technologies and Airbnb are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Alphabet, Sanofi & Mondelez International

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Sanofi (SNY) and Mondelez International, Inc. (MDLZ).

Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study

by Zacks Equity Research

Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.

Sanofi (SNY) Stock Outperforms Industry YTD: What's Next?

by Zacks Equity Research

Continued strong sales of Dupixent, contributions from new product launches and positive pipeline progress are likely to keep Sanofi's (SNY) stock afloat.

Sanofi (SNY) Signs Deal to Co-Develop Teva's IBD Candidate

by Zacks Equity Research

Sanofi (SNY) and Teva enter into a collaboration deal to co-develop and co-commercialize the latter's inflammatory bowel disease candidate, TEV'574.

Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine

by Zacks Equity Research

Per the terms of the deal, Sanofi (SNY) and J&J will co-fund current and future R&D costs to develop a potential first-in-class vaccine against extraintestinal pathogenic E. coli.

AstraZeneca (AZN) Key Drugs to Aid Growth, Pipeline Strong

by Zacks Equity Research

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up.

Baudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag

by Zacks Equity Research

FDA grants the Orphan Drug designation to Baudax (BXRX) for its lead pipeline candidate, TI-168, to treat Hemophilia A patients with inhibitors.

The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J

by Zacks Equity Research

AbbVie, Lilly, Sanofi, Merck and J&J are included in this Analyst Blog.